Date: 28 Apr 2026 to 29 Apr 2026
2nd Neuroscience Innovation Partnering & Licensing Summit
Event Notes:
Advance Best- or First- in Class Candidates, Raise Capital & Drive Disease Modification
From transformative genetic therapies in rare diseases to neuroimmunology candidates addressing residual unmet needs in MS, and novel target validation driving confidence in disease modification for neurodegeneration, best- and first-in-class neuroscience opportunities continue to shape and drive pharma investment.
Returning for its second year, following the inaugural launch that attracted over 100 attendees, the 2nd Neuroscience Innovation Partnering & Licensing Summit is strategically timed to facilitate multiple high-impact, in-person meetings without the distractions of a broader, less focused setting.
Who Attends This Differentiated Business Development Initiative?
- Global Pharma: Heads of Business Development, Search & Evaluation, and Asset Scouting for Neuroscience – comparing pipelines and enabling technologies to fuel future innovation.
- Innovative Biotech: C-level executives and BD leaders across neurodegeneration, psychiatry, neuro-oncology, and pain – seeking feedback, validation, and strategic partnerships with pharma and investors.
